Abstract: Transthyretin (TTR) is a homotetrameric protein that is found in the plasma and cerebrospinal fluid. Dissociation of TTR tetramers sets off a downhill cascade of amyloid formation through polymerization of monomeric TTR. Interestingly, TTR has an additional, biologically relevant activity, which pertains to its ability to slow the progression of amyloid beta (Ab) associated pathology in transgenic mice. In vitro, both TTR and a kinetically stable variant of monomeric TTR (M-TTR) inhibit the fibril formation of Ab 1-40/42 molecules. Published evidence suggests that tetrameric TTR binds preferentially to Ab monomers, thus destabilizing fibril formation by depleting the pool of Ab monomers from aggregating mixtures. Here, we investigate the effects of M-TTR on the in vitro aggregation of Ab 1-42 . Our data confirm previous observations that fibril formation of Ab is suppressed in the presence of substoichiometric amounts of M-TTR. Despite this, we find that sub-stoichiometric levels of M-TTR are not bona fide inhibitors of aggregation. Instead, they co-aggregate with Ab to promote the formation of large, micron-scale insoluble, non-fibrillar amorphous deposits. Based on fluorescence correlation spectroscopy measurements, we find that M-TTR does not interact with monomeric Ab. Two-color coincidence analysis of the fluorescence bursts of Ab and M-TTR labeled with different fluorophores shows that M-TTR co-assembles with soluble Ab aggregates and this appears to drive the coaggregation into amorphous precipitates. Our results suggest that mimicking the co-aggregation activity with protein-based therapeutics might be a worthwhile strategy for rerouting amyloid beta peptides into inert, insoluble, and amorphous deposits.
Introduction
The misfolding of soluble monomeric proteins into stable amyloid fibers is linked to a wide number of neurodegenerative diseases. 1 The most well-known of these is Alzheimer's disease (AD), which affects over five million individuals in the US alone. 2 A primary hallmark of AD is the presence of amyloid deposits consisting of proteolytic fragments of the amyloid precursor protein (APP), with the major species being the 40 or 42 residues variants of this peptide designated as amyloid beta (Ab 1-40/42 ) peptide. 3 Since their initial identification, the Ab 1-40 /42 systems have been the focus of in vitro and in cell investigations with particular focus on the driving forces and mechanisms of Ab 1-40/42 aggregation.
1 Ab 1-40/42 is one of many proteins that undergo misfolding and aggregation to form amyloid fibrils that are also associated with neurodegenerative or systematic disorders. Among the earliest examples of a protein whose misfolding and aggregation were directly linked to disease is the homotetrameric protein transthyretin (TTR), a protein carrier of the thyroid hormone that is abundant in human serum and cerebrospinal fluid (CSF). 4, 5 Interestingly, TTR is also relevant to the pathophysiology of Ab 1-40/42 in AD as it is one of three CSF proteins originally identified by Goldgaber et al. to interact with Ab peptides. 6 The other two proteins are apolipoproteins (Apo-) E and J. 6 Of the three, TTR is the most abundant, and is found at concentrations 3-to 10-times higher than Apo-E and Apo-J, respectively. 7 Early studies sug-
gested that TTR appears to be the principal Ab sequestering protein. 8 In later work, when TTR was co-expressed as a transgene in muscles of C. elegans expressing Ab regulated by the same promoter, it suppressed the paralysis phenotype seen when the worms were transgenic only for Ab. 9, 10 It was subsequently
shown that genetically programmed tissue-specific over-expression of wild-type human TTR suppressed the behavioral and neuropathologic abnormalities seen in the APP23 transgenic mouse model of human Ab deposition. 11 Additionally, when APP23 and APPswe/PS1DE9 transgenic AD model mice were crossed with TTR knockouts, the pace of development of Ab deposition was accelerated.
11,12
In vitro studies have shown that the wild-type TTR protein delays or reduces Ab fibril formation. 8, [13] [14] [15] [16] [17] [18] [19] [20] [21] As noted above, TTR can itself drive amyloid formation. The obligatory step driving TTR amyloid fibril formation is the dissociation of tetrameric TTR into monomers. 22, 23 Kelly and coworkers have established that dissociation of TTR tetramers is the rate-limiting step because amyloid formation proceeds as a downhill process upon tetrameter dissociation. 4 Additionally, M-TTR was observed to reduce oligomeric induced toxicity of Ab to a greater extent than tetrameric TTR in human neuroblastoma cells and rat primary neurons. 33 In the context of the CSF, both the tetrameric and monomeric forms of wild-type TTR have significance, albeit for different reasons. The tetramer is the functional form, whereas the monomer is the pathological form. However, the ability of M-TTR to inhibit the formation of Ab fibrils raises the intriguing possibility that tetramer dissociation and the consequent accrual of monomers might have a protective role from the standpoint of Ab toxicity. Suppression of Ab fibril formation could also be an alternative way to protect against the toxicity of monomeric TTR while also slowing the progression of Ab pathology. In light of these intriguing possibilities, which remain conjectures, we sought to obtain a more complete mechanistic understanding of the differences or similarities between how TTR and M-TTR impact Ab aggregation. This work builds on previous studies, which suggest that TTR and perhaps M-TTR act as sensors and scavengers of Ab oligomers. 19 Our focus here is on the Ab 1-42 (Ab42) alloform since it is the more toxic of the two prominent Ab species (Ab 1-40 vs. Ab 18 These results suggest that the inhibition of Ab fibril formation might be different for the two TTR species, although the nature of these differences remains unclear. 18 Here, we examine how the genetically engineered M-TTR alters the complex aggregation behavior of Ab42 in vitro. Our results show that while substoichiometric levels of M-TTR suppress Ab42 fibril formation, these molecules promote the formation of large, micron-scale amorphous aggregates through a co-aggregation mechanism. We uncover the mechanistic underpinnings that lead to the co-aggregation of M-TTR with Ab42 and the resulting amorphous deposits. The potent inhibition of fibril formation exhibited by M-TTR may serve as a model for understanding how molecules can be diverted and re-routed from fibril formation pathways. The formation of inert amorphous co-aggregates may be a desirable outcome when compared to the formation of protofibrils and fibrils that can act as seeds and recruit soluble molecules and/or serve as infectious, prion-like agents. [34] [35] [36] Our mechanistic insights regarding M-TTR may help with the design of protein-based therapeutics that divert Ab42 molecules from fibril forming pathways.
Results

Effect of M-TTR on Ab42 fibril formation
We examined the effect of M-TTR on the kinetics of fibril formation of Ab42 by monitoring the rate of increase in thioflavin T (ThT) fluorescence. Figure 1 shows a representative trace for the rate of increase in ThT fluorescence as measured in a solution comprising of 8 mM Ab42. This kinetic trace shows the characteristic lag and growth phase that is suggestive of a complex nucleated polymerization mechanism for fibril formation. In the presence of 4 mM M-TTR, we observed a 13-fold decrease in the ThT fluorescence at the endpoint of the reaction when compared to the absence of M-TTR. These data are reproducible in varying, sub-stoichiometric amounts of M-TTR incubated with Ab42 at the start of the reaction, thus demonstrating that M-TTR does indeed suppress fibril formation of Ab42, in accord with previous findings. 18 
Effect of M-TTR on fibrillar versus non-fibrillar aggregation of Ab42
ThT fluorescence is insensitive to the formation of non-fibrillar aggregates. To measure the possibility of other modes of aggregation, we monitored the rate of loss of tetramethylrhodamine (TMR) fluorescence using dye-labeled Ab42 molecules. 37 We used labeled Ab42 molecules where the TMR is covalently attached to a lysine residue on the N-terminus of Ab42. TMR molecules self-quench when they are brought into close proximity, in this case by the oligomerization and/or aggregation of the Ab42 peptides to which the TMR molecules are attached. 37 Unlike the ThT assay, the rate of loss of TMR fluorescence is not limited to the detection of amyloid fibril formation. Instead, any assembly or aggregation process that brings the TMR molecules into close proximity will lead to a quenching of its fluorescence. 37, 38 This assay is therefore sensitive to the presence of amyloid-like and non-amyloid-like aggregates and the sensitivity range will span the gamut from oligomers to large aggregates comprising of thousands of molecules. Figure 2 shows a comparison of the rates of loss of TMR fluorescence of TMR-Ab42 (2 mM) in the absence versus presence of M-TTR (1 mM). The kinetics of aggregation of Ab42 in the absence and presence of M-TTR are quite similar in the early phases of the reaction, as monitored by the rates of loss of TMR fluorescence. However, we observe significant deviations between the two traces during the growth phase-a feature that is reproducible as shown in Supporting Information, Figure S1 . The "growth phase" in a TMR fluorescence assay quenching experiment corresponds to the formation of large aggregates, and this refers to species that are on the order of 1 mm or larger. The apparent aggregation rate in the growth phase is slowed in the presence of M-TTR.
M-TTR does not significantly alter the overall solubility of Ab42
The impact of a ligand on aggregation and phase separation can be quantified by measuring the effect of the ligand on the saturation concentration for the largescale assembly. 39 The saturation concentration c s is the concentration of soluble species including monomers and other soluble aggregates that are in equilibrium with the insoluble aggregates. 38, 40 We used the intrinsic TMR fluorescence at the end of the aggregation reaction, measured after incubation for four days Figure S1 shows the reproducibility of these traces from independent measurements, each with different, albeit sub-stoichiometric amounts of M-TTR.
to estimate the values of c s for Ab42 in the absence versus presence of M-TTR. The results are shown in Figure 3 (A). We find that the value of c s for Ab42 increases from 335 nM in the absence of M-TTR to 485 nM in the presence of M-TTR. Thus, M-TTR increases the solubility of monomeric Ab42 molecules by a factor of approximately 1.5, which is a modest effect when compared to the >13-fold reduction in the extent of Ab42 fibril formation (Fig. 1 ). This suggests that M-TTR does not suppress aggregation per se, although it does suppress fibril formation.
Effect of M-TTR on monomeric Ab42
To assess the interaction between M-TTR and Ab42 we performed fluorescence correlation spectroscopy (FCS) measurements of Alexa488-labeled Ab42. Measurements were made in the absence and presence of M-TTR with freshly purified monomeric Ab42 isolated by size exclusion chromatography in 3 mM NaOH (see Methods). Experiments were carried out rapidly following NaOH dilution, before the Ab42 monomer pool could be significantly depleted. If M-TTR were to bind monomeric Ab42, we would expect to see a measurable increase in the diffusion time of the fluorescently labeled Ab42. Figure 3(B) shows that the diffusion of Alexa488-Ab42 at time t 5 0 is 65 ms. This diffusion time, which is in accord with previous measurements, 41 does not change in the presence of M-TTR. Thus, the binding of M-TTR to predominantly monomeric Ab42 that would lead to a 1:1 complex must be weak or negligible. These results are consistent with results showing that the early stages of Ab42 aggregation are not impacted by the presence of M-TTR (Fig. 2) .
Effect of M-TTR on the morphology of the Ab42 aggregates
The data presented above indicate that M-TTR destabilizes Ab42 fibrillar species while allowing for or even promoting other forms of aggregation. To test this hypothesis, we first used transmission electron microscopy (TEM) to examine the morphology of aggregates collected from the end points of the two experiments summarized in Figure 1 . In the absence of M-TTR, Ab42 forms fibrils that are several microns long and 6-10 nm wide [ Fig. 4(A) ]. However, when Ab42 is incubated with M-TTR, the aggregates formed are non-fibrillar [ Fig. 4(B) ]. The TEM images do not reveal whether these are homotypic aggregates of Ab42 and/or M-TTR or co-aggregates of the two molecules. To answer this question, we used confocal fluorescence microscopy to test for colocalization of M-TTR and Ab42 in the precipitates of the M-TTR-Ab42 concentration of soluble aggregates of Ab42 is significantly reduced in the presence of M-TTR.
M-TTR binds preferentially to soluble Ab42 aggregates
We investigated whether M-TTR and Ab42 interact at the oligomeric level. To examine this possibility, we used two-color fluorescence burst and coincidence analysis on a sample consisting of Alexa488-labeled M-TTR and TMR-labeled Ab42. This assay is similar to the fluorescence burst analysis previously described, except that the sample components are labeled with two different fluorophores and the sample is assayed for coincident bursts in the two fluorescent channels. Coincident bursts indicate colocalization of the constituent biomolecules. We mixed 400 nM TMR-Ab42 and 200 nM Alexa488-M-TTR with 8 mM unlabeled-Ab42 and 4 mM unlabeled M-TTR. Figure 7 shows the photon count traces in TMR and the Alexa488 channels, respectively. The fluorescence bursts observed in the Alexa488 channel (which are of M-TTR) correlate with those observed in the TMR channel (which are of Ab42). Co-localization of M-TTR and Ab42 points to interactions, albeit of unresolved stoichoimetries, between M-TTR and soluble aggregates of Ab42 that would appear to be a heterogenous mixture of species.
Discussion
The overall picture that emerges from our study is as follows: M-TTR suppresses fibril formation of Ab42 but it does not bind to monomeric Ab42, nor does it impact the earliest stages of aggregation. Additionally, M-TTR has a minimal effect on the solubility limit of Ab42. Instead, it appears that the ability of M-TTR to suppress fibril formation of Ab42 derives from its ability to bind preferentially to soluble aggregates of Ab42. These soluble aggregates may well be precursors of fibril formation or provide sites for secondary nucleation. [42] [43] [44] [45] Our data are consistent with the soluble aggregates being diverted from the fibrilforming pathway as evidenced by the formation of large, amorphous co-aggregates with M-TTR. Therefore, we conclude that instead of being an inhibitor of Ab42 aggregation, M-TTR suppresses fibril formation and re-routes soluble aggregates of Ab42 molecules into co-aggregates that are non-fibrillar and amorphous.
Our findings are concordant with so-called polysteric linkage that has been enunciated in the classical literature on binding and linkage phenomena, 39, 46 and in the context of nucleic acid binding proteins. 47 This refers to the preferential binding of a ligand to heterogeneous mixtures of soluble aggregates of specific or undefined sizes. Polysteric linkage is a specialized circumstance of polyphasic linkage, where the former refers to preferential binding to specific species without necessarily altering phase boundaries, whereas polyphasic linkage refers to preferential binding that leads to changes in the positions of phase boundaries. 39 The concept of polyphasic linkage was recently demonstrated in the context of profilin binding to exon1 spanning constructs of the protein hutingtin. 48 The FCS analysis presented here using labeled M-TTR and Ab42 provides insights regarding the interactions that cause Ab42 to supersaturate the soluble phase. Since M-TTR is larger than Ab42 monomer (13.8 vs. 4.5 kDa), the stronger Ab42 signal in the complexes indicates that high Ab42/M-TTR molar ratios are most consistent with larger soluble aggregates of Ab42 being bound by small oligomers (or monomers) of M-TTR. A precise analysis of the size distribution is confounded by the bleed through from the TMR channel into the Alexa488 channel, which is the result of spectral overlap. Finding dyes that are bright and have minimal overlap is challenging, but new analysis methods and time-dependent coincidence measurements should allow us to uncover the precise size distributions of Ab42 aggregates that are targeted by M-TTR. We observed several fluorescence bursts in the Ab42 channel that were not associated with corresponding bursts in the M-TTR channel. This is possibly indicative of soluble aggregates of Ab42 that were not bound by M-TTR. Alternatively, it is possible that since the fluorescence bursts are only visible when there are sufficient numbers of labeled molecules in an aggregates, the co-localization of smaller oligomers may not be detectable. In other words, a soluble aggregate of Ab42 with a single unlabeled M-TTR bound would not register coincident bursts and would therefore appear (incorrectly) to be an Ab42 species that is not bound to M-TTR.
Our data can be used for crude quantitative estimates of the sizes of the species that are being recognized by M-TTR. The average brightness quantified in terms of the photon counts per molecule would be 10 kHz for a typical Ab42 monomer. Figure  6 shows that the photon bursts correspond to counts of 1 MHz, which is two orders of magnitude larger than the counts for monomeric Ab42. Accounting for the fact that only 5% of the Ab42 molecules are fluorescently labeled, we estimate that the species being recognized by M-TTR include, on average, approximately 10 3 Ab42 molecules. Such species would be analogous to the micellar species observed for Ab 49 and/or precursors of fibrillar species that are about 100 nm in diameter, 50 or secondary nuclei that have been proposed to be the determinants of the lagphase in Ab aggregation. [42] [43] [44] [45] 51 In this regard, it is worth noting that species in the 25-50 nm range have been observed for huntingtin exon 1 (Httex1) spanning fragments and have been designated as Sphase species. It is possible that the species that are preferentially recognized by M-TTR are analogous to the recently observed S-phase species of Httex1. 48 The fact that monomeric TTR (as opposed to the genetically engineered constitutive monomer M-TTR used in this study) can inhibit fibril formation by Ab and possibly other amyloid precursors suggests that there may be a general ability for aggregation-prone proteins to interact in a heterotypic manner, whereas conformational specificity is required for nucleation and templating that leads to fibril formation via homotypic associations. 52 We conjecture that oligomers of M-TTR might display peptide structures that resemble Ab sequences to interfere with the specific interactions required for fibrils, generating aggregates that are less likely to form fibrils. Our results are analogous to observations in the field of inorganic crystal formation. 53 Mixtures of calcium and orthophosphate will rapidly undergo crystallization to form predominantly needle-like crystals, with a small number of amorphous aggregates. However, in the presence of several different phosphate and phosphonate salts, the same reaction forms amorphous structures devoid of crystallinity, as indicated by electron microscopy and electron diffraction intensities. These amorphous structures are similar to the early stage assemblies observed during "rapid mixing" experiments of calcium and orthophosphate. 54 Since amyloids are semi-crystalline, we suggest that the introduction of co-precipitating species is likely a general mechanism to inhibit crystallization, in which these co-precipitants act to either kinetically or thermodynamically inhibit the conformational rearrangements needed to form ordered solids. The potent inhibition of fibril formation by M-TTR can serve as a model for understanding how amyloid pathways can be reshaped. Indeed, TTR and M-TTR have been shown to prevent amyloid formation in other amyloid-prone proteins, including HypF-N 55 and the curli protein CsgA, a bacterial amyloid forming protein that is responsible for biofilm formation. 56 Human wild-type tetrameric TTR and the engineered M-TTR inhibit CsgA amyloid formation in vitro. They also inhibit amyloid-dependent biofilm formation in two different bacterial species. As in other studies, M-TTR was found to be more potent as an inhibitor of amyloid formation. The fact that TTR is able to prevent amyloid fibril formation in multiple, apparently unrelated amyloidogenic proteins suggests that there are general principles to be gleaned from its mechanism of action. Importantly, these principles are likely to be broadly applicable.
Materials and Methods
Preparation of Ab42 and TTR
Unlabeled and TMR-labeled Ab 1-42 peptides, which were chemically synthesized, were purchased from Keck Foundation (Yale University). The peptides were purified by reverse-phase liquid chromatography using a C18 column in water/acetonitrile media. The purified peptides were lyophilized and resuspended in 6 M GdmHCl. The Ab42 peptides were further purified by size exclusion chromatography using a Superdex peptide column (GE Healthcare) in 3 mM NaOH. The predominantly monomeric fraction was selected for subsequent experiments. Engineered recombinant monomeric human TTR (F87M/ L110M TTR) was produced in an E. coli expression system. 32 The protein was purified by gel filtration on a Superdex-75 column (Amersham-Pharmacia, Sweden) in 10 mM phosphate buffer (sodium) pH 7.6, 100 mM KCl, 1 mM EDTA and stored at 48C at a concentration of 0.1-0.5 mg/mL in the dark. The protein was analyzed on a LC-ESI mass spectrometer to confirm its nature by molecular weight and re-purified by gel filtration 1-3 days before the assays to ensure that no aggregates were present in the starting material. 22 The final M-TTR solution (42 mM) was prepared in phosphate buffered saline (PBS) at pH 7.4.
Measurement of aggregation kinetics
A 40 mM stock solution of unlabeled Ab42 or 20 mM stock solution of TMR-labeled Ab42 (TMR-Ab42) prepared in 3 mM NaOH was diluted to the desired final concentration into PBS pH 7.4 containing 1 mM EDTA, and 5 mM b-mercaptoethanol (bME).
We measured the kinetics of fibril formation by quantifying the gain in ThT fluorescence. The concentration of ThT used was 2 mM. We measured the kinetics of overall aggregation using the TMR fluorescence of TMR-Ab42. The samples were incubated inside the fluorimeter in a clean glass test tube with continuous stirring in a temperature-controlled cuvette holder. Aggregation of unlabeled and TMRlabeled Ab42 samples were monitored continuously using fluorescence of ThT (excitation wavelength of 438 nm, emission maximum at 480 nm) or TMR (excitation wavelength of 520 nm, emission maximum of 600 nm). All samples were stirred continuously using a micro stir bar.
Measurement of saturation concentration of Ab42
Ab42 peptides, 2 mM of TMR-Ab42, in the absence or presence of 1 mM M-TTR prepared in PBS buffer at pH 7.4 containing 1 mM EDTA, 5 mM bME were incubated for four days at room temperature with continuous stirring. The solutions were centrifuged at 2000g for 20 min. The TMR fluorescence of the supernatants was then recorded. Concentrations of the TMR-Ab42 were determined by comparing their fluorescence with that of known concentrations of free TMR. Note that measurements of aggregation kinetics using TMR quenching indicate that aggregate formation plateaus by 24 h, thus four days is sufficient time to reach equilibrium.
Measurement of diffusion time using FCS
Fresh solutions of 400 nM Alexa488-Ab42, 4 mM unlabeled Ab42 were mixed with or without 4 mM unlabeled TTR for FCS measurements. The diffusion times were obtained from the fit of the autocorrelation data using a single diffusion model.
Transmission electron microscopy of aggregates
Ab42 (8 mM) was incubated in absence or in presence of 4 mM M-TTR in PBS buffer at pH 7.4 containing 1 mM EDTA, 5 mM bME, and 2 mM ThT for two days at RT with continuous stirring. The aggregation of this solution was monitored using ThT fluorescence. The aggregates were then resuspended in the solution by a brief vortexing. A 10 mL droplet was placed on a Formvar carbon-coated 200 mesh copper grid (Electron Microscopy Sciences) and allowed to adsorb for 1 min. The grid was washed twice in distilled water. Finally, the grid was negatively stained in 0.5% uranyl acetate for 1 min and then dried in a desiccator overnight at room temperature. The images were collected using a JEOL 100CX transmission electron microscope equipped with an AMT digital camera.
Confocal microscopy of the M-TTR-ab precipitates
Co-aggregation of soluble Ab42 and M-TTR was measured using confocal microscopy in a Zeiss Confocor 2. For these measurements 400 nM TMRAb42 1 200 nM Alexa488-M-TTR 1 8 mM unlabeled Ab42 1 4 mM unlabeled M-TTR were incubated in PBS buffer at pH 7.4 containing 1 mM EDTA and 5 mM bME were incubated at RT with continuous stirring for two days. A 40 mL aliquot of this sample was placed on a glass cover slip for 1 h prior to imaging. The fluorescence imaging of Alexa488 and TMR were performed in two separate detection channels.
Fluorescence burst analysis
Alexa488-labeled Ab42 (400 nM) mixed with unlabeled Ab42 (8 mM) in PBS buffer at pH 7.4 containing 1 mM EDTA, 5 mM bME, and 2 mM ThT for four days at room temperature with continuous stirring. The aggregation was monitored continuously in the fluorimeter. The solution was centrifuged at 2000g for 20 min. The supernatant was collected for the fluorescence burst measurement by FCS. FCS measurements were performed in a Zeiss confocor 2 microscope equipped with the FCS capability. The photon count traces in the FCS measurement mode was monitored continuously with 100 ms binning time.
Fluorescence burst coincidence analysis
Coincidence of Ab42 and TTR in the soluble aggregates was measured using coincidence of the fluorescence bursts. In these measurements, 400 nM TMRAb42 and 200 nM Alexa488-M-TTR were mixed with 8 mM unlabeled Ab42 and 4 mM unlabeled M-TTR. The solutions prepared in PBS buffer at pH 7.4 containing 1 mM EDTA and 5 mM bME were incubated at room temperature with continuous stirring for two days prior to measurements. The fluorescence of Alexa488 and TMR were monitored in two separate detection channels using FCS.
